Zacks Research Downgrades Bayer Aktiengesellschaft (OTCMKTS:BAYRY) to Hold

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Separately, Wall Street Zen upgraded shares of Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Up 0.7%

Bayer Aktiengesellschaft stock opened at $7.61 on Monday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.73 and a current ratio of 1.13. Bayer Aktiengesellschaft has a 52-week low of $4.79 and a 52-week high of $8.70. The firm has a 50 day moving average price of $8.06 and a two-hundred day moving average price of $7.67. The firm has a market cap of $29.90 billion, a price-to-earnings ratio of -7.85, a PEG ratio of 3.62 and a beta of 0.90.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.10. Bayer Aktiengesellschaft had a negative net margin of 7.61% and a positive return on equity of 15.44%. The firm had revenue of $12.42 billion during the quarter, compared to analyst estimates of $10.79 billion. Equities analysts predict that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.